Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
The antiproliferative effect of tandem somatostatin receptor (SSTR) activation, epidermal growth factor receptor (EGFR) inhibition, and induction of DNA damage was analyzed using octreotide (OCT), a SSTR agonist, the clinical DNA methylating agent temozolomide (TMZ), Iressa, an EGFR inhibitor, and dual EGFR-DNA targeting agents termed "combi-molecules". Using SSTR-expressing glioma cells harbouring low levels of EGFR (U87MG) or transfected to overexpress EGFR (U87/EGFR) or a variant (U87/EGFRvIII), we showed that Iressa, alone or in combination with the DNA damaging agent TMZ, and combi-molecules RA2 and RA5 inhibited EGF-induced phosphorylation of EGFR in U87MG and more moderately in U87/EGFR and U87/EGFRvIII transfected cells. This translated into equivalent levels of Erk 1/2 inhibition. Activation of SSTRs with OCT did not modulate the effects of the various treatments on Erk 1/2 phosphorylation. Likewise, SSTR activation did not alter TMZ- or DNA-damaging combi-molecules, RA2 and RA5, induced p53 activation nor upregulation. However, SSTR activation significantly shifted TMZ-, RA2- and RA5-induced cell-cycle arrest to earlier phases (i.e., G2/M to late S, late S to S, S to G1). Further analysis showed that apoptosis was not induced. This was in agreement with the fact that p53 activation did not induce Bax upregulation nor did EGFR inhibition promote Bad dephosphorylation. Moreover, enhancement of survivin, an anti-apoptotic protein, expression was observed. The results in toto suggest that the combination of SSTR activation with EGFR inhibition and DNA damage affects cell-cycle progression but a disconnection between the targeted signalling pathways in these brain tumour cells precludes synergistic cell-killing by the triple growth inhibitory events.
Watt
H L
HL
Department of Medicine, McGill University Health Centre/Royal Victoria Hospital, Montreal, QC, Canada.
Rachid
Z
Z
Jean-Claude
B J
BJ
D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D004249:DNA Damage; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000494:pharmacology; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D005434:Flow Cytometry; D000077156:Gefitinib; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005910:Glioma / Q000473:pathology; D006801:Humans; D008954:Models, Biological; D009154:Mutation / Q000235:genetics; D015282:Octreotide / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D011799:Quinazolines / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D000077204:Temozolomide; D013997:Time Factors; D014162:Transfection / Q000379:methods
D000970:Antineoplastic Agents; D011799:Quinazolines; D004815:Epidermal Growth Factor; D003606:Dacarbazine; D066246:ErbB Receptors; D015282:Octreotide; D000077156:Gefitinib; D000077204:Temozolomide
EMBO J. 2000 Jul 3;19(13):3159-67
10880430
Clin Cancer Res. 2008 Aug 15;14(16):5000-5
18698017
J Cell Biochem. 2004 Jul 1;92(4):656-63
15211564
Ann N Y Acad Sci. 2004 Apr;1014:121-31
15153426
Int J Cancer. 1998 Apr 13;76(2):259-66
9537589
Cancer Res. 2004 Aug 15;64(16):5753-9
15313916
Acta Pharmacol Sin. 2009 Jul;30(7):1053-9
19575008
J Med Chem. 2007 May 31;50(11):2605-8
17472358
Int J Cancer. 2004 Nov 10;112(3):484-91
15382076
Curr Opin Cell Biol. 2006 Dec;18(6):609-15
16934447
Cancer Chemother Pharmacol. 2003 Jan;51(1):1-10
12497200
Neuropathology. 2006 Jun;26(3):178-87
16771172
Anticancer Drugs. 2009 Sep;20(8):659-67
19581798
Cell Signal. 2009 Mar;21(3):428-39
19070659
Br J Cancer. 2004 Jan 12;90(1):236-44
14710235
Breast Cancer Res Treat. 2005 Jul;92(2):175-86
15986128
Br J Cancer. 2004 Sep 13;91(6):1066-73
15365562
Anticancer Drugs. 2006 Feb;17(2):165-71
16428934
J Neurooncol. 1999 Mar;42(1):45-57
10360478
J Biol Chem. 1999 May 21;274(21):15186-93
10329727
Curr Opin Cell Biol. 2004 Dec;16(6):670-8
15530779
Anticancer Drugs. 2007 Feb;18(2):171-7
17159603
J Neurochem. 1995 Nov;65(5):1997-2005
7595483
Life Sci. 1995;57(13):1249-65
7674817
Eur J Endocrinol. 1999 Oct;141(4):396-408
10526255
J Neuroendocrinol. 2002 Jun;14(6):458-71
12047721
Mol Endocrinol. 1996 Dec;10(12):1688-96
8961277
Mol Cell Endocrinol. 2006 Aug 15;256(1-2):34-9
16828967
Diabetes. 1999 Jan;48(1):77-85
9892225
J Biol Chem. 2004 Jul 9;279(28):29004-12
15123617
Biochem Pharmacol. 2005 Aug 15;70(4):511-9
15982640
Neuropeptides. 2001 Feb;35(1):1-23
11346306
Cancer Chemother Pharmacol. 2003 Jan;51(1):11-20
12497201
Mol Pharmacol. 2004 Sep;66(3):478-91
15322239
J Pharmacol Exp Ther. 2002 Oct;303(1):238-46
12235257
Mol Cell Endocrinol. 2008 May 14;286(1-2):75-87
17997029
J Physiol Paris. 2000 Jan-Feb;94(1):57-62
10761690
J Med Chem. 2003 Dec 4;46(25):5546-51
14640561
Prostate. 2004 Apr 1;59(1):13-21
14991862
J Pharmacol Exp Ther. 2004 Dec;311(3):1163-70
15358812
Neuro Oncol. 2008 Jun;10(3):309-19
18445700
Cancer Res. 2004 Aug 1;64(15):5355-62
15289342
Cancer. 2005 Feb 15;103(4):869-73
15641034
Oncogene. 2003 Nov 24;22(53):8581-9
14634620
Brain Res Mol Brain Res. 2001 Feb 19;87(1):12-21
11223155
J Pharmacol Exp Ther. 2001 Mar;296(3):832-40
11181914
Mol Cancer Ther. 2009 Feb;8(2):394-406
19190119
Br J Cancer. 2004 Aug 16;91(4):795-802
15280923
Int J Cancer. 2008 Sep 15;123(6):1364-75
18561312